A new solution for testing brain drugs

Anna Lagunas

Fundació Institut de Bioenginyeria de Catalunya, Barcelona, Spain

Finding treatments for brain diseases is highly challenging because the brain is protected by a natural barrier that blocks most medicines from entering. This barrier plays a crucial role in shielding the brain from harmful substances but also prevents many potentially effective treatments from reaching their target. Current methods for testing new treatments, such as experiments on animals or simplified lab models, often fail to provide accurate results. Animal testing raises ethical concerns, and the outcomes frequently do not predict how medicines will behave in humans.

To solve this problem, this project proposes a new device that mimics the natural barrier protecting the brain. This device, called a blood-brain barrier-on-a-chip model, re-creates the human brain's protective environment more accurately than previous methods. Using advanced sensors integrated into the device, it allows scientists to measure how well medicines can pass through the barrier, combining light-based tools and electrical readings. This innovation enables researchers to test brain-targeted therapies on a more realistic and predictive model, improving the reliability of results and reducing the need for animal testing.

The ultimate goal of this technology is to speed up the discovery of treatments for conditions like brain diseases, while lowering costs and making the process more ethical. By replicating the conditions of the human brain more closely, this device can identify which medicines are more likely to succeed in clinical trials, potentially saving years of research and significant expenses. The developers are now working to improve the device so it meets market demands, secure its intellectual property, and validate its performance for eventual use in healthcare.

This groundbreaking technology represents a shift towards more humane and precise drug testing methods. By offering a better way to develop treatments for brain conditions, it could transform how therapies are created, benefiting patients and advancing medical research worldwide.

Blood-brain barrier-on-a-chip (BBB-oC) for drug testing of brain-targeting delivery

Stage 1